In this report, we correlated S100A9+ MDSCs and TAMs to EGFR-TKI treatment response in patients with EGFR mutated lung adenocarcinoma and addressed the question as to whether this MDSC is a source of TAMs. The gene discussed is EGFR; the disease is lung adenocarcinoma.